June 29, 2010
The U.S. Food and Drug Administration announced Friday it has approved the first rapid-result blood test for the hepatitis C virus. The test is manufactured by OraSure Technologies, which already has approval to sell it in Europe. FDA approved the OraQuick Hepatitis C Rapid Antibody Test for the testing of whole blood drawn from a vein of patients age 15 and older. Unlike existing HCV tests, the OraQuick test strip delivers results in 20 minutes and does not need to be processed by a laboratory. "Approval of OraQuick means that more patients can be notified of their HCV infection faster so that they can consult with their physicians for appropriate health measures," said Jeffrey Shuren, M.D., J.D., director of FDA's Center for Devices and Radiological Health. "Getting faster treatment is an important public health step to control this dangerous disease." The new test should begin shipping to hospitals and other customers by late July or early August, said OraSure CEO Douglas Michels. The company continues to seek approval for similar HCV tests using finger-prick blood samples and oral fluid. To read FDA's announcement, visit www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm217318.htm.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|CROI 2017 Preview: New Research on HIV Cure and Treatment|
|Don't Get Left Behind: New Scientific Findings to Be Presented at CROI 2017|
|What to Expect for CROI 2017|
|Targeting Latently Infected Cells via IFITM1|
|Eliciting Accurate Responses About Substance Use|
|Diabetes Rate 3.8% Higher in People Living With HIV in National U.S. Comparison|